AbSTRACT. We explored the potential of fusion of hepatic locus control region 1 (HCR-1) with HCR-2 to express B-domain-deleted human factor VIII (FVIII) in four cell lines. B-domain-deleted human FVIII expression was controlled by HCR-1/HCR-2, followed by liver specific and ubiquitous promoters. Chimera enhancer HCR-1/HCR-2, followed by cytomegalovirus (CMV) promoter, gave 2-fold more FVIII expression in all cell lines (105.6 ± 2.8 for Hek-293, 68.8 ± 3.8 for HepG2, 34.8 ± 1.3 for CHO, and 27.2 ± 1.6 ng�mL -1 �10 6 cells -1 for L.N.) when compared to the vector with CMV alone (54.8 ± 3.3 for Hek-293, 32.4 ± 1.2 for HepG2, 18.6 ± 1.1 for CHO, and 10.1 ± 1.7 ng�mL -1 �10 6 cells -1 for L.N.). Elongation factor 1-α gene and human CMV promoters were more efficient than the promoters from the human α-1-antitrypsin gene, and fviii Enhancer/promoter strengthens factor VIII expression was less efficient in hepatic cell lines. HCR-1/HCR-2, followed by strong promoters, increases FVIII expression in vitro. Our results underscore the importance of cis sequences for enhancing in vitro FVIII expression; this may be helpful for designing new strategies to improve heterologous expression systems.
AbSTRACT. We explored the potential of fusion of hepatic locus control region 1 (HCR-1) with HCR-2 to express B-domain-deleted human factor VIII (FVIII) in four cell lines. B-domain-deleted human FVIII expression was controlled by HCR-1/HCR-2, followed by liver specific and ubiquitous promoters. Chimera enhancer HCR-1/HCR-2, followed by cytomegalovirus (CMV) promoter, gave 2-fold more FVIII expression in all cell lines (105.6 ± 2.8 for Hek-293, 68.8 ± 3.8 for HepG2, 34.8 ± 1.3 for CHO, and 27.2 ± 1.6 ng�mL -1 �10 6 cells -1 for L.N.) when compared to the vector with CMV alone (54.8 ± 3.3 for Hek-293, 32.4 ± 1.2 for HepG2, 18.6 ± 1.1 for CHO, and 10.1 ± 1.7 ng�mL -1 �10 6 cells -1 for L.N.). Elongation factor 1-α gene and human CMV promoters were more efficient than the promoters from the human α-1-antitrypsin gene, and fviii ally active. Moreover, HCR-1 has a matrix attachment region and liver-specific enhancer elements, which can significantly increase gene expression (Simonet et al., 1993) . Allan et al. (1995) demonstrated that a second region HCR (HCR-2) is located 27 kb downstream of HCR-1; it functions as a hepatic enhancer and has activity similar to HCR-1.
We analyzed the efficiency of various constructions to express FVIII. Five different constructions containing FVIIIDB were generated with an expression cassette that includes HCR-1 and HCR-2 linked by tata box followed either by liver-specific promoters (hAAT or physiological FVIII promoter) or by ubiquitous promoters (cytomegalovirus, CMV or elongation factor 1-α, EF1-α). This is the first time that expression of FVIII has been demonstrated using plasmid vectors containing HCR-1 and HCR-2 combined with different promoters.
MATERIAl AnD METhoDS

Plasmid constructions
In order to generate the FVIII plasmid vectors, full-length FVIII-cDNA from ATCC (accession number K01740) was used as a template for the polymerase chain reaction (PCR).
pn-FVIII/hC-EGFP: the heavy chain (HC) was cloned into a pN2 plasmid vector (Clonthec, USA) in fusion with an enhanced green fluorescent protein (EGFP). The HC was amplified using sense primer 5'-GTCGACATGCAAATAGAGCTCTCCACC-3' and reverse primer 5'-GATATCTGAATTCTGGGAGAAGCTTCTTG-3'. The HC is from nucleotide 172 to 2466 (including 24 amino acids of B-domain). The amplified fragment was cloned between SalI and EcoRV sites of the multiple cloning site (MCS) of mammalian expression vector pEGFP (Clonthec, USA). The MCS region is between the CMV promoter and the EGFP.
pSecTag-FVIII/lC-c-myc: the light chain (LC) was cloned into pSecTagB in fusion with the IgK signal peptide (upstream) and c-myc (downstream). The LC was amplified using the sense primer 5'-GTAATCCAAAACCCACCAGTCTTGAAACG-3' and the reverse primer 5'-CCCTCGAGCGTAGAGGTCCTGTGCCTC-3'. The LC is from nucleotide 5140 to 7227, including 34 amino acids of the B-domain. The fragment was cloned between EcoRV and XhoI sites of MCS of mammalian expression vector SecTagHygroB (Invitrogen, USA). The MCS region is between the IgK signal peptide for protein secretion and the c-myc gene.
pcDnA3.1-hCR-1-2-FVIIIDb: The FVIIIDB was cloned into a pcDNA3.1 plasmid under control of the CMV promoter. The deletion of nucleotides 2428-5067 from the FVIII full-length cDNA results in a functional FVIII protein. These nucleotides code for amino acids 760 to 1639, which represent part of the B-domain of the protein. HCR-1 and HCR-2 were obtained from the vector pBS-HCR-1-2, kindly provided by Dr. Torsten Tonn, Institute for Transfusion Medicine and Immunohaematology, Frankfurt, Germany. To clone the region HCR-1-2 into the pcDNA3.1-cmv-FVIIIDB, the pBS-HCR-1-2 vector was digested with the enzymes EcoRV and XhoI to release the HCR-1-2 fragment. This fragment was treated with klenow enzyme to form blind ends and cloned into the vector pcDNA-cmv-FVIIIDB. This vector was previously digested with MluI (restriction site located upstream to the CMV promoter) and treated with the klenow enzyme. The HCR-1-2 fragment and the vector (pcDNA-cmv-FVIIIDB) were linked with T4 ligase (Invitrogen, German) to form the vector pcDNA-HCRcmv-FVIIIDB. The fragments encoding the hAAT, EF1-α and fviii promoters were amplified by PCR using specific primers (Table 1) .
The amplified products were digested with MunI and NotI and cloned into pcDNA3.1-HCR-FVIIIDB previously digested with the same restriction enzymes (MunI and NotI excise the original CMV of the pcDNA3.1 vector). For the fviii promoter, a minimal sequence consisting of nucleotides -44 to +148 was found to retain the wild-type transcriptional activity in human hepatocellular carcinoma (HepG2) cells (McGlynn et al., 1996) . This promoter was used to form vector pcDNA-HCR-fviii-FVIIIDB. For the hAAT promoter, the main part of the promoter sequence that included the hepatocyte-specific regulatory response elements was known to be nucleotides -488 to +20. This region was used to generate vector pcDNA-HCRhAAT-FVIIID (Mendel et al., 1991; Kalsheker et al., 2002) . The fviii and hAAT promoters were generated by PCR from human embryonic kidney epithelial (Hek-293) cell genomic DNA. A fragment encoding the EF1-α promoter was generated by PCR from the plasmid pEFIRES-P to generate pcDNA-HCR-EF1-α-FVIIIDB. The identities and correct orientation of the promoter sequences were confirmed by sequencing. Figure 1 shows the schematic representation of all constructions.
Primers Sequence Table 1 . Oligonucleotides used in amplification reaction of promoters fviii, hAAT and EF1-α. 
Cells
All cell lines were obtained as seed stocks from the German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany (DSMZ; www.dsmz.de) or from the ATCC (www.atcc.org), Cell Biology Collection. They were further expanded and stored in liquid nitrogen. Hek-293 (DSMZ ACC 305), CHO (DSMZ ACC 110), HepG2 (DSMZ ACC 180), and L.N. 4159 (ATCC CRL-10998) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Germany), supplemented with 2 mM GlutaMAX™-I (Invitrogen) and with 10% heat-inactivated fetal bovine serum (Biochrom AG, Berlin, Germany). All cultures were grown as monolayers at 37°C in 5% CO 2 and saturated humidity.
Plasmid transfections
Transfections were performed in a six-well plate at a cell confluence of around 70%, and 19 µL Lipofectamine 2000 (Invitrogen), 1.5 µg endotoxin-free plasmid DNA (purified with QIAgen Plasmid Kit, called Endo free maxi), and 1 mL serum-reduced medium (OptiMEM, Gibco) were mixed (transfection mix) in each well. After a 30-min incubation, the transfection mix was added to the cells, which were incubated overnight (up to 14 h). Transfection was stopped by collecting the mix and incubating the cells with normal medium. For co-transfection of FVIII-HC and FVIII-LC, 1 μg/mL calcium ionophore, 0.1 μg/mL phorbol 12-myristate 13-acetate (PMA) and 0.05 μg/mL von Willebrand factor (vWF) were added to the culture medium 12 h after transfection.
RT-PCR analysis
Total RNAs (2 μg) from each sample were reverse transcribed using random primers and Superscript II Reverse Transcriptase (RT, Gibco BRL). Then, cDNAs (2 μL) were used as a template for subsequent PCR experiments. The primers used to amplify a 526-bp fragment of FVIII-HC were 5'-CTTGGACAGTTTCTACTG-3' (forward) and 5'-GACGGACATCAGTGATTC-3' (reverse); the primers used to amplify a 974-bp fragment of FVIII-LC were 5'-CATGTGTTCACTGTACG-3' (forward) and 5'-GGTGTGAAGGAGTCTTG-3' (reverse). A 517-bp fragment of human β-actin was amplified as an internal control. P1F: 5'-GGCATCGTGATGGACTCCG-3'; P1R: 5'-GCTGGAAGGTGGACAGCGA-3'. All primers used in RT-PCR were located in different exons. The PCR profile was 94°C for 2 min, followed by 34 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 60 s, with a final extension step at 72°C for 5 min. The PCR products were then separated by 1% agarose gel electrophoresis and gene expression was analyzed.
Immunocytochemical analysis of intracellular FVIII
The FVIII-HC was fused with EGFP. Expression of EGFP in transfected cell lines was examined on an Axioskop 2.0 Zeiss microscope (Germany) equipped with an Axiocam camera (Zeiss). The FVIII-LC was fused with c-myc. Expression of c-myc was detected with an anti-cmyc monoclonal antibody (Invitrogen, USA) and a secondary Cy3-conjugated anti-mouse IgG (Chemicon, USA). The cells were washed with phosphate-buffered saline (PBS), pH 7.2, and fixed with 2% paraformaldehyde, containing 0.3% Triton X-100, for 10 min at 37°C; PBS washings were done more three times. The cells were left in contact with blocking solution (2% bovine Enhancer/promoter strengthens factor VIII expression serum albumin and 5% goat serum in PBS) for 1 h at room temperature, and then incubated for 1 h at 37°C in primary antibody diluted in blocking solution (anti-c-myc = 10 µg/mL). Following incubation with the primary antibody, the cells were washed four times with PBS, incubated for 1 h at 37°C with the secondary antibody (1 µg/mL in blocking solution), and washed again with PBS. Cover slips were mounted in 1 mg/mL ρ-phenylenediamine in 90% glycerol and observed using epifluorescence microscopy (Axioskop 2, Carl Zeiss).
FVIII activity quantification
Supernatants were harvested and analyzed for FVIII expression using a two-stage chromogenic assay (Immuno GmbH, Germany). The FVIII concentrations are given as IU, as defined by the World Health Organization; 1 IU/mL FVIII is equivalent to 200 ng/mL.
RESulTS
The comparison of FVIII-hC and FVIII-lC cloned in separated plasmids with FVIIIDb vector
FVIII protein production by co-transfection of pN-FVIII/HC-EGFP and pSecTag-FVIII/ LC-c-myc was compared with the production by transfection of pcDNA3.1-FVIIIDB. pcDNA3.1-FVIIIDB is a hybrid molecule of HC and LC joined by a B-domain fragment of 14 amino acids. The FVIIIDB gave the highest expression levels in all transfected cells. The co-transfection of FVIII-LC and FVIII-HC produced very low FVIII activity in culture. However, when the co-transfected cells were treated with PMA/calcium ionofore/vWF FVIII activity rose in all transfected cells (Figure 2) . However, the highest FVIII levels were found in the cells transfected with pcDNA3.1-FVIIIDB. 
Detection of FVIII-hC and FVIII-lC by RT-PCR and immunocytochemistry
RT-PCR was used to detect FVIII-HC and FVIII-LC mRNA in low level FVIII activity co-transfected cells. All co-transfected cell lines had mRNA of both chains (Figure 3) , and immunocytochemistry was used to detect intracellular FVIII protein. The cotransfected cells with FVIII-HC and FVIII-LC without adding PMA, calcium ionophore and vWF were analyzed. FVIII-LC was detected with an anti-c-myc monoclonal antibody and secondary Texas Red-conjugated anti-mouse IgG, and FVIII-HC was in fusion with EGFP. Figure 4 shows a fluorescent microscope image of CHO, Hek-293 and HepG2 cells expressing FVIII-HC and FVIII-LC 48 h after transfection. Immunocytochemistry showed evidence of intra-cellular co-localization of both FVIII chains in the cell. This suggests that these co-transfected cells produce the FVIII chains, but at low quantities. When the cells were treated with PMA/calcium ionofore/vWF, the FVIII was detectable in the supernatants of the cell lines. 
Evaluation of promoter activity by measuring FVIII and activity
The potential of liver enhancer/promoters for producing FVIII in liver cells was also examined. We profiled the activity of enhancer/liver-promoters in comparison with enhancer/ubiquitous-promoters for expression of FVIII in hepatic and non-hepatic cell lines. We used vector pcDNA3.1-FVIIIDB, which gives the highest FVIII levels. The chimera enhancer region HCR-1-2 was cloned in this vector, followed by hAAT, fviii, EF1-α, and CMV promoter (Figure 1 ). FVIII activity was measured to profile the activity of generalized and liver-specific promoters for expression of FVIII in different cell lines. The CMV and EF1-α promoters drive expression of a variety of proteins, and they are not tissue-specific. In contrast, promoters fviii and hAAT are controlled by liver-specific factors. FVIII activity was measured in 10 6 cells after a 48-h cultivation for 48 h. The results demonstrated different levels of expression ( Figure 5 ). The efficiency of each promoter and cell line differed markedly. The combination HCR-1-2/EF1-α expression constructs gave the best yield (184.4 ± 7.1 for Hek-293, 133.6 ± 3.0 for HepG2, 38.4 ± 1.9 for CHO, and 20.8 ± 1.7 ng�mL -1
�10
6 cells for L.N.), followed by HCR-1-2/CMV (105.6 ± 2.8 for Hek-293, 68.8 ± 3.8 for HepG2, 34.8 ± 1.3 for CHO, and 27.2 ± 1.6 ng�mL -1 �10 6 cells for L.N.). Both HCR-1-2/EF1-α and HCR-1-2/CMV cassette expression contributed to increasing the FVIII expression level in all cell lines. The combination of enhancer HCR-1-2 with the liver-specific promoter hAAT and with the fviii promoter gave significantly lower FVIII expression (HCR-1-2/hAAt: 39 ± 3.1 for Hek-293, 16.6 ± 2.2 for HepG2, 35 ± 1.8 for CHO, and 6.6 ± 1.7 mL/10 6 cells for L.N.; HCR-1-2/fviii: 33.4 ± 2.6 for Hek-293, 18 ± 1.6 for HepG2, 22.8 ± 2.1 for CHO, and 6.8 ± 1.5 mL/10 6 cells for L.N.) ( Figure 5A ). The FVIII activity produced by pcDNA-HCR-1-2/CMV-FVIIIDB was on average two times higher than the FVIII activity produced by pcDNA-CMV-FVIIIDB in all cell lines ( Figure 5B ).
DISCuSSIon
We used a DNA plasmid system, which is easy and fast, to probe a combination of two hepatic enhancer regions (HCR-1 and HCR-2) followed by different promoters and the recombinant protein for transient expression.
First, we used separate plasmid vectors to deliver the LC and HC of FVIII to three cell lines. In all transfected cell lines, immunocytochemistry indicated that the proteins of the two chains were co-localized intracellularly. Without PMA, calcium ionophore and vWF, FVIII was not detectable in the supernatants of these transfected cell cultures. After addition of these secretion factors, the three cell lines gave about 20 ng/mL FVIII activity; however, this value is four times lower than the FVIII activity obtained with FVIIIDB-vector transfected cells. This result indicates that PMA, calcium ionophore and vWF improve FVIII-HC and FVIII-LC expression and/or secretion. Burke et al. (1986) has shown that LC and HC cloned in identical vectors give different expression levels. The LC contains sequences that inhibit transcription, causing an imbalance in the expression of the chains, which may be the cause of the lack of activity in transfected cells (Chen et al., 2007) . There are a number of factors that could account for this chain imbalance, including differences in vector gene transfer, transgene transcription, and/or protein translation and secretion.
Due to the low FVIII activity obtained with HC and LC vectors, we decided to modify the expression vector containing the FVIII B deleted domain (pCDNA-FVIIIDB) to obtain better FVIII expression levels. We investigated whether pCDNA-FVIIIDB together with liverspecific enhancer HCR-1-2 and different promoters could increase gene expression of FVIII in various different cell lines. The promoters were EF1-α, CMV, hAAT, and fviii. To better focus the experiments, we used truncated hAAT and fviii promoter sequences that retained the minimal transcription initiation function (Mendel et al., 1991; McGlynn et al., 1996; Kalsheker et al., 2002) . We found that all four promoters were capable of directing FVIII expression in hepatocyte cell lines, as well as in Hek-293 and CHO cells.
The EF1-α promoter produced the highest FVIII levels in all cell lines. By comparison, the CMV promoter had relatively little activity, and the hAAT and fviii promoters had even less.
We also found that the shortest functional sequences of the fviii and hAAT promoters were also active in the non-hepatic Hek-293 cell line. This is not surprising, in view of the fact that expression of the hAAT gene has been documented in extra-hepatic sites, including undifferentiated monocytes, macrophages, intestinal epithelial cells, and respiratory epithelium (Perlmutter et al., 1985; Molmenti et al., 1993) . It is possible that when these promoters were truncated, fragments responsible for their tissue specificity were removed. A truncated hAAT promoter was shown to be equally active in hepatocytes and non-hepatic NIH3T3, HeLa and Hek-293 cells (Okuyama et al., 1996; Nash et al., 2004) .
Factor VIII is mainly expressed in the liver (Wion et al., 1985; Lewis et al., 1985 Lewis et al., , 1987 . However, FVIII is also expressed at moderate levels in the spleen, kidney, and lymph nodes (McGlynn et al., 1996) . Transcriptional activity of both the minimal fviii promoter and the minimal hAAT promoter probably requires hepatocyte nuclear factor 1 (HNF1α), and it is enhanced by the absence of its homologous isoform HNF1β (Mendel et al., 1991; McGlynn et al., 1996) . HNF1α predominates in hepatocytes and seems to be responsible for the high expression of fviii or hAAT in the liver. However, HNF1α is absent in hepatoma cells (ReyCampos et al., 1991) . Its absence could contribute to the low level of FVIII expression that we found with the fviii and hAAT promoters.
We conclude that HCR-1-2 followed by CMV promoter doubles FVIII activity levels in cell lines when compared to the CMV vector without HCR-1-2. The combination of HCR-1 and HCR-2 can help optimize in vitro rFVIII gene expression. It will be of interest to determine if the cis sequence can function in a similar manner with heterologous cDNAs.
